Global pharmaceutical companies have bemoaned for years India's capricious policies on prices and patents. Now the government needs billions of dollars for its “Make in India” program, why can't the industry get a fairer deal? When it comes to intellectual property, it's now understood—and grudgingly ...
Read more: A $300 billion reason India's drug price cap will stay